Prognostic Factors of Survival in a Randomized Phase III Trial (MPACT) of Weekly nab-Paclitaxel Plus Gemcitabine Versus Gemcitabine Alone in Patients With Metastatic Pancreatic Cancer

BACKGROUND. nab-Paclitaxel in combination with gemcitabine has emerged as a new treatment option for patients with metastatic pancreatic cancer (MPC), based on superiority over gemcitabine demonstrated in the phase III MPACT trial. Previously, Karnofsky performance status (KPS) score and the presenc...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncologist
Main Authors: Tabernero, Josep, Chiorean, E. Gabriela, Infante, Jeffrey R., Hingorani, Sunil R., Ganju, Vinod, Weekes, Colin, Scheithauer, Werner, Ramanathan, Ramesh K., Goldstein, David, Penenberg, Darryl N., Romano, Alfredo, Ferrara, Stefano, Von Hoff, Daniel D.
Formato: Artigo
Idioma:Inglês
Publicado em: AlphaMed Press 2015
Assuntos:
Gastrointestinal Cancer
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4319641/
https://ncbi.nlm.nih.gov/pubmed/25582141
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2014-0394
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados